A specialized preclinical CRO providing translational PK, PD, efficacy and safety models in NHPs, Virscio conducts non-GLP proof of concept, efficacy, and IND-enabling GLP safety studies to accelerate and de-risk path to clinical for small molecules, biologics and CGT therapies. We apply unrivaled NHP access and extensive therapeutic domain expertise to drive decision making and program value. We offer molecular and histopathology services supporting primate and nonprimate test systems.